trending Market Intelligence /marketintelligence/en/news-insights/trending/gnbC-fdiJtmIlK-WL35aZg2 content esgSubNav
In This List

Alcon Q2 net sales up 2% YOY

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Alcon Q2 net sales up 2% YOY

Alcon Inc. said net sales increased 2% year on year to $1.86 billion in the second quarter driven by surgical and vision care sales.

Core diluted earnings per share for the company, previously under Novartis AG, however, slipped to 47 cents for the three months ended June 30, compared to 52 cents in the year-ago period.

For the first half of 2019, net sales totaled $3.64 billion, up from $3.60 billion in the same period last year. Core diluted EPS fell to 98 cents during the six months from $1.10 in 2018.

Alcon reiterated its full year outlook unveiled in May. The company expects net sales for the full year to grow between 3% to 5% on a constant currency basis.

Novartis completed the spinoff of Alcon, its eye care business, in April. Alcon shares started trading on the SIX Swiss Exchange and the New York Stock Exchange on April 9.